UBS Maintains Neutral on Humana, Lowers Price Target to $326
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on Humana (NYSE:HUM) and lowers the price target from $334 to $326.
April 25, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Kevin Caliendo maintains a Neutral rating on Humana and lowers the price target from $334 to $326.
The reduction in price target by UBS suggests a more conservative outlook on Humana's stock value in the short term, potentially leading to a negative impact on its stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100